Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Assets: 2019-2025

Historic Current Assets for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $1.1 billion.

  • Beam Therapeutics' Current Assets rose 16.18% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 16.18%. This contributed to the annual value of $878.1 million for FY2024, which is 27.49% down from last year.
  • Beam Therapeutics' Current Assets amounted to $1.1 billion in Q3 2025, which was down 6.54% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Current Assets peaked at $1.3 billion during Q4 2021, and registered a low of $514.6 million during Q1 2021.
  • For the 3-year period, Beam Therapeutics' Current Assets averaged around $1.1 billion, with its median value being $1.1 billion (2023).
  • Per our database at Business Quant, Beam Therapeutics' Current Assets spiked by 351.07% in 2021 and then dropped by 27.49% in 2024.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Current Assets stood at $1.3 billion in 2021, then dropped by 14.15% to $1.1 billion in 2022, then increased by 10.81% to $1.2 billion in 2023, then decreased by 27.49% to $878.1 million in 2024, then grew by 16.18% to $1.1 billion in 2025.
  • Its Current Assets stands at $1.1 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.